These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31190658)

  • 21. Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study.
    Brady KT; Sonne SC; Anton R; Ballenger JC
    J Clin Psychiatry; 1995 Mar; 56(3):118-21. PubMed ID: 7883730
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact and challenges of the 2018 MHRA statement on the use of sodium valproate in women of childbearing age during the first year of implementation, in a UK epilepsy centre.
    Davies P; Reuber M; Grunewald R; Howell S; Dickson J; Dennis G; Shanmugarajah P; Tsironis T; Brockington A
    Seizure; 2020 Jul; 79():8-13. PubMed ID: 32380376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alternatives to valproate in girls and women of childbearing potential with Idiopathic Generalized Epilepsies: state of the art and guidance for the clinician proposed by the Epilepsy and Gender Commission of the Italian League Against Epilepsy (LICE).
    Mostacci B; Ranzato F; Giuliano L; La Neve A; Aguglia U; Bilo L; Durante V; Ermio C; Monti G; Zambrelli E; Lodi MAM; Galimberti CA
    Seizure; 2021 Feb; 85():26-38. PubMed ID: 33418162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is the Medicines and Healthcare products Regulator Agency (MHRA) guidance on sodium valproate acceptable to women of childbearing age?
    Morrison I; Cork H; Smith P; Campbell C; Megan McTiernan M; White K
    J R Coll Physicians Edinb; 2020 Jun; 50(2):114-117. PubMed ID: 32568279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review.
    Chengappa KN; Chalasani L; Brar JS; Parepally H; Houck P; Levine J
    Clin Ther; 2002 Oct; 24(10):1576-84. PubMed ID: 12462287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Valproate risk form-Surveying 215 clinicians involving 4775 encounters.
    Angus-Leppan H; Moghim MM; Cock H; Kinton L; Synnott Wells M; Shankar R
    Acta Neurol Scand; 2020 Jun; 141(6):483-490. PubMed ID: 32072612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors influencing lithium versus valproate prescription preference in the maintenance treatment of bipolar patients: a report from the Italian Early Career Psychiatrists (SOPSI-GG).
    Buoli M; Gattoni E; Collantoni E; Monteleone AM; Solmi M; Longo L; Ribolsi M; Santambrogio J; Bersani FS; Aguglia A; Serafini G; Signorelli MS; Dell'Osso B; Luciano M; Galderisi S
    Int J Psychiatry Clin Pract; 2021 Mar; 25(1):82-89. PubMed ID: 33380246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evolution and characteristics of the use of valproate in women of childbearing age with bipolar disorder: Results from the FACE-BD cohort.
    Samalin L; Godin O; Olié E; Etain B; Henry C; Pelletier A; Poinso F; Encely L; Mazer N; Roux P; Loftus J; Gard S; Bennabi D; Polosan M; Schwitzer T; Aubin V; Schwan R; Passerieux C; Bougerol T; Dubertret C; Aouizerate B; Haffen E; Courtet P; Bellivier F; Leboyer M; ; Llorca PM; Belzeaux R
    J Affect Disord; 2020 Nov; 276():963-969. PubMed ID: 32745833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sodium valproate induced acute pancreatitis in a bipolar disorder patient: a case report.
    Huang W; Ren X; Shen F; Xing B
    BMC Pharmacol Toxicol; 2019 Nov; 20(1):71. PubMed ID: 31783774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Off-label use of sodium valproate for schizophrenia.
    Horowitz E; Bergman LC; Ashkenazy C; Moscona-Hurvitz I; Grinvald-Fogel H; Magnezi R
    PLoS One; 2014; 9(3):e92573. PubMed ID: 24664210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Valproic acid prescription trends among females of childbearing age in Estonia: A 14-year nationwide prescription database study.
    Kurvits K; Laius O; Uusküla M; Haldre S; Rakitin A
    Seizure; 2020 Jan; 76():28-31. PubMed ID: 31982850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder.
    Macritchie KA; Geddes JR; Scott J; Haslam DR; Goodwin GM
    Cochrane Database Syst Rev; 2001; (3):CD003196. PubMed ID: 11687047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
    Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE
    Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expert advice on the management of valproate in women with bipolar disorder at childbearing age.
    Anmella G; Pacchiarotti I; Cubała WJ; Dudek D; Maina G; Thomas P; Vieta E
    Eur Neuropsychopharmacol; 2019 Nov; 29(11):1199-1212. PubMed ID: 31590972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prescribing Trends for Valproate Among Pregnant Women: A Cross-sectional Study in 2013 and 2016 Using the French Health Insurance Database.
    Degremont A; Kerbrat S; Balusson F; Jonville-Bera AP; Ringa V; Travers D; Tillaut H; Leray E; Oger E; Biraben A; Polard E
    Neurology; 2022 May; 98(21):e2163-e2173. PubMed ID: 35379759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of risk minimisation measures for valproate: A cross-sectional survey among physicians in Europe.
    Toussi M; Isabelle B; Tcherny-Lessenot S; de Voogd H; Dimos V; Kaplan S
    Pharmacoepidemiol Drug Saf; 2021 Mar; 30(3):283-291. PubMed ID: 33216434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risks of neurobehavioral teratogenicity associated with prenatal exposure to valproate monotherapy: a systematic review with regulatory repercussions.
    Gentile S
    CNS Spectr; 2014 Aug; 19(4):305-15. PubMed ID: 24571806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect size of lithium, carbamazepine, and sodium valproate in child and adolescent bipolar 1 disorder during manic phase: A prospective open-label study.
    Singh RK; Sinha VK; Chaudhury S
    Ind Psychiatry J; 2019; 28(2):185-197. PubMed ID: 33223710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sodium valproate: its use in primary psychiatric disorders.
    McElroy SL; Keck PE; Pope HG
    J Clin Psychopharmacol; 1987 Feb; 7(1):16-24. PubMed ID: 3102563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.